|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
CN115925931A
(zh)
*
|
2015-08-14 |
2023-04-07 |
默沙东公司 |
抗tigit抗体
|
|
KR102543118B1
(ko)
|
2016-05-27 |
2023-06-14 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
RU2764548C2
(ru)
|
2016-08-09 |
2022-01-18 |
Кимаб Лимитед |
Анти-icos антитела
|
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
MX2019006072A
(es)
|
2016-11-30 |
2019-08-14 |
Oncomed Pharm Inc |
Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
|
|
CN111050788A
(zh)
*
|
2017-02-28 |
2020-04-21 |
西雅图基因公司 |
抗tigit抗体
|
|
LT3618863T
(lt)
*
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
CN110913906A
(zh)
|
2017-05-02 |
2020-03-24 |
默沙东公司 |
抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
JP7348072B2
(ja)
|
2017-06-01 |
2023-09-20 |
コンピュジェン リミテッド |
三重併用抗体療法
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
IL272227B2
(en)
*
|
2017-07-27 |
2025-09-01 |
iTeos Belgium SA |
Anti-tigit antibodies
|
|
CN111051347B
(zh)
|
2017-09-29 |
2021-12-21 |
江苏恒瑞医药股份有限公司 |
Tigit抗体、其抗原结合片段及医药用途
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
TWI877769B
(zh)
*
|
2017-12-30 |
2025-03-21 |
英屬開曼群島商百濟神州有限公司 |
抗tigit抗體及其作為治療和診斷的用途
|
|
SG11202004521QA
(en)
|
2018-02-06 |
2020-06-29 |
I Mab Biopharma Us Ltd |
Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
|
|
KR102825164B1
(ko)
|
2018-03-27 |
2025-06-26 |
브리스톨-마이어스 스큅 컴퍼니 |
자외선 신호를 사용한 단백질 농도의 실시간 모니터링
|
|
TWI754157B
(zh)
*
|
2018-07-25 |
2022-02-01 |
大陸商信達生物製藥（蘇州）有限公司 |
抗ｔｉｇｉｔ抗體及其用途
|
|
EP3841123A2
(en)
*
|
2018-08-23 |
2021-06-30 |
Seagen Inc. |
Anti-tigit antibodies
|
|
CN109384846B
(zh)
*
|
2018-09-25 |
2020-03-03 |
合肥瑞达免疫药物研究所有限公司 |
能够结合tigit的抗体或其抗原结合片段及用途
|
|
MX2021004356A
(es)
|
2018-10-18 |
2021-05-31 |
Merck Sharp & Dohme Llc |
Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
|
|
MA54089A
(fr)
|
2018-10-31 |
2022-02-09 |
Merck Sharp & Dohme |
Anticorps anti-pd-1 humain et procédés d'utilisation associés
|
|
JP7503056B6
(ja)
|
2018-11-07 |
2024-07-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
|
|
WO2020127377A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional anti-pd-1/il-7 molecule
|
|
SG11202107474RA
(en)
*
|
2019-01-07 |
2021-08-30 |
iTeos Belgium SA |
Anti-tigit antibodies
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
WO2020172658A1
(en)
|
2019-02-24 |
2020-08-27 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
|
CN109734806B
(zh)
*
|
2019-03-15 |
2022-07-01 |
安徽安科生物工程（集团）股份有限公司 |
一种全人源抗huTIGIT单克隆抗体及其应用
|
|
KR20220012292A
(ko)
|
2019-05-23 |
2022-02-03 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 배양 배지를 모니터링하는 방법
|
|
CA3146986A1
(en)
*
|
2019-07-15 |
2021-01-21 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-tigit antibodies and application thereof
|
|
CN117683133A
(zh)
|
2019-09-03 |
2024-03-12 |
百奥泰生物制药股份有限公司 |
一种抗tigit免疫抑制剂及应用
|
|
CN114728171A
(zh)
*
|
2019-11-05 |
2022-07-08 |
默克专利有限公司 |
抗tigit抗体及其应用
|
|
US20240279342A1
(en)
*
|
2019-11-15 |
2024-08-22 |
Surface Oncology, Inc. |
Compositions and methods for immunotherapy
|
|
TW202136287A
(zh)
|
2019-12-17 |
2021-10-01 |
法商Ｏｓｅ免疫治療公司 |
包含il-7變體之雙官能分子
|
|
MX2022008412A
(es)
|
2020-01-07 |
2022-08-08 |
Univ Texas |
Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
|
|
CN115052622B
(zh)
*
|
2020-01-21 |
2026-03-06 |
夏尔巴生物技术(杭州)有限公司 |
重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
|
|
KR20220132555A
(ko)
|
2020-01-29 |
2022-09-30 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Nrg1 융합체를 사용한 암 치료를 위한 egfr/her2 티로신 키나제 억제제 및/또는 her2/her3 항체의 사용
|
|
KR20220133238A
(ko)
|
2020-01-29 |
2022-10-04 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
|
|
MX2022010910A
(es)
*
|
2020-03-06 |
2022-10-07 |
Regeneron Pharma |
Anticuerpos anti-gitr y usos de estos.
|
|
EP4119162A4
(en)
|
2020-03-13 |
2023-08-23 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
PVRIG-BINDING PROTEIN AND ITS MEDICAL USES
|
|
EP4147053B1
(en)
|
2020-05-07 |
2026-01-28 |
Institut Curie |
Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
|
|
CN111995681B
(zh)
*
|
2020-05-09 |
2022-03-08 |
华博生物医药技术（上海）有限公司 |
抗tigit的抗体、其制备方法和应用
|
|
WO2021257124A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
WO2021258337A1
(en)
|
2020-06-24 |
2021-12-30 |
Huahui Health Ltd. |
Human monoclonal antibodies against tigit for immune related diseases
|
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
|
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
|
JP2023544410A
(ja)
|
2020-10-05 |
2023-10-23 |
ブリストル－マイヤーズ スクイブ カンパニー |
タンパク質を濃縮するための方法
|
|
US20240002500A1
(en)
*
|
2020-11-23 |
2024-01-04 |
Guangdong Fapon Biopharma Inc. |
Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof
|
|
WO2022112198A1
(en)
|
2020-11-24 |
2022-06-02 |
Worldwide Innovative Network |
Method to select the optimal immune checkpoint therapies
|
|
WO2022124864A1
(ko)
*
|
2020-12-10 |
2022-06-16 |
주식회사 유틸렉스 |
항-tigit 항체 및 이의 용도
|
|
WO2022148781A1
(en)
|
2021-01-05 |
2022-07-14 |
Institut Curie |
Combination of mcoln activators and immune checkpoint inhibitors
|
|
CN114907476A
(zh)
*
|
2021-02-09 |
2022-08-16 |
上海医药集团股份有限公司 |
抗tigit抗体及其用途
|
|
MX2023011964A
(es)
|
2021-04-09 |
2024-01-08 |
Ose Immunotherapeutics |
Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
|
|
EP4320156A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
CA3217279A1
(en)
|
2021-05-04 |
2022-11-10 |
Olga Ignatovich |
Anti-tigit antibodies and methods of use thereof
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
US12558406B2
(en)
|
2021-05-10 |
2026-02-24 |
Medimabbio Inc. |
Anti-TIGIT antibodies and use thereof
|
|
CA3227854A1
(en)
*
|
2021-07-28 |
2023-02-02 |
Elpiscience (Suzhou) Biopharma, Ltd. |
Novel anti-sirpa antibodies
|
|
CN118871463A
(zh)
|
2021-07-28 |
2024-10-29 |
基因泰克公司 |
用于治疗癌症的方法和组合物
|
|
KR20240043786A
(ko)
*
|
2021-08-09 |
2024-04-03 |
바이오세우스 인크. |
항-tigit 항체 및 이의 용도
|
|
MX2024001877A
(es)
|
2021-08-10 |
2024-02-28 |
Kymab Ltd |
Tratamiento de dermatitis atopica.
|
|
JP2024535793A
(ja)
|
2021-09-15 |
2024-10-02 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
Ｐｄ－１に特異的に結合するタンパク質及びその医薬的使用
|
|
US20240376207A1
(en)
|
2021-09-15 |
2024-11-14 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
|
|
US20250084155A1
(en)
|
2021-09-29 |
2025-03-13 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
WO2023138639A1
(zh)
*
|
2022-01-24 |
2023-07-27 |
原启生物科技(上海)有限责任公司 |
靶向tigit的抗原结合蛋白及其用途
|
|
KR20240156411A
(ko)
|
2022-03-09 |
2024-10-29 |
브리스톨-마이어스 스큅 컴퍼니 |
치료 단백질의 일시적 발현
|
|
CA3259975A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
CA3250812A1
(en)
*
|
2022-04-29 |
2023-11-02 |
Merck Sharp & Dohme Llc |
Stable formulations of anti-ILT4 antibodies or antigen-binding fragments thereof in combination with anti-PD-1 antibodies and their methods of use
|
|
JP2025523387A
(ja)
|
2022-06-07 |
2025-07-23 |
ジェネンテック， インコーポレイテッド |
抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
|
|
WO2024003360A1
(en)
|
2022-07-01 |
2024-01-04 |
Institut Curie |
Biomarkers and uses thereof for the treatment of neuroblastoma
|
|
EP4565610A1
(en)
|
2022-08-02 |
2025-06-11 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
|
WO2024041639A1
(en)
*
|
2022-08-26 |
2024-02-29 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies targeting tigit and uses thereof
|
|
EP4681729A4
(en)
|
2023-03-15 |
2026-07-15 |
Shanghai Mabgen Biotech Ltd |
PHARMACEUTICAL COMPOSITION CONTAINING A PD-1/PVRIG/TIGIT BINDING PROTEIN AND ITS MEDICAL USE
|
|
JP2026512425A
(ja)
|
2023-03-30 |
2026-04-16 |
オーエスイー・イミュノセラピューティクス |
免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
|
|
WO2024200820A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|
|
WO2025242836A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
|
|
WO2025262250A1
(en)
|
2024-06-20 |
2025-12-26 |
Negio Therapeutics |
Guanfacine derivatives and their uses
|
|
WO2026068705A1
(en)
|
2024-09-26 |
2026-04-02 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
|